130 related articles for article (PubMed ID: 38085958)
1. PReferentially Expressed Antigen in MElanoma Expression in Uterine and Ovarian Carcinosarcomas.
Alrohaibani A; Yu Y; Gao L; McLean KM; Hetts J; Saglam O
Int J Gynecol Pathol; 2024 May; 43(3):284-289. PubMed ID: 38085958
[TBL] [Abstract][Full Text] [Related]
2. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
3. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
4. Folate Receptor Alpha Is Preferentially Expressed in the Carcinoma Component of Endometrial Carcinosarcomas: A Potential Target for Adjuvant Therapy.
Hanley KZ; Horowitz IR; Gordon A; Meisel J; Khanna N
Int J Gynecol Pathol; 2021 Sep; 40(5):501-509. PubMed ID: 33323854
[TBL] [Abstract][Full Text] [Related]
5. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Zhao S; Bellone S; Lopez S; Thakral D; Schwab C; English DP; Black J; Cocco E; Choi J; Zammataro L; Predolini F; Bonazzoli E; Bi M; Buza N; Hui P; Wong S; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Facchetti F; Falchetti M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Mane S; Angioli R; Terranova C; Quick CM; Edraki B; Bilgüvar K; Lee M; Choi M; Stiegler AL; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12238-12243. PubMed ID: 27791010
[TBL] [Abstract][Full Text] [Related]
6. Expression of adhesion molecules and the proliferative activity of carcinosarcoma of the ovary.
Hirano H; Kizaki T; Ito T; Okimura A; Yamanegi K; Nakasho K
Anticancer Res; 2014 Dec; 34(12):7351-6. PubMed ID: 25503171
[TBL] [Abstract][Full Text] [Related]
7. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D; Devouassoux-Shisheboran M; Ledermann JA; Leitao MM; Powell MA; Poveda A; Beale P; Glasspool RM; Creutzberg CL; Harter P; Kim JW; Reed NS; Ray-Coquard I
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S55-60. PubMed ID: 25341582
[TBL] [Abstract][Full Text] [Related]
8. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms.
Murray SK; Clement PB; Young RH
Am J Surg Pathol; 2005 Feb; 29(2):157-66. PubMed ID: 15644772
[TBL] [Abstract][Full Text] [Related]
9. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics.
Kedzia W; Pruski D; Iwaniec K; Przybylski M; Friebe Z; Rajpert-Kedzia H
Folia Histochem Cytobiol; 2012; 50(4):513-8. PubMed ID: 23264213
[TBL] [Abstract][Full Text] [Related]
10. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.
McCluggage WG
Int J Gynecol Cancer; 2002; 12(6):687-90. PubMed ID: 12445244
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma (malignant mixed müllerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases.
Costa MJ; Khan R; Judd R
Arch Pathol Lab Med; 1991 Jun; 115(6):583-90. PubMed ID: 1710102
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of matrix metalloprotease-7 in each component of uterine carcinosarcoma.
Tanimoto H; Shigemasa K; Sasaki M; Katayama H; Kusumi I; Parmley TH; O'Brien TJ; Ohama K
Oncol Rep; 2000; 7(6):1209-12. PubMed ID: 11032915
[TBL] [Abstract][Full Text] [Related]
13. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Predolini F; Pettinella F; Masserdotti A; Zammataro L; Altwerger G; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Clin Cancer Res; 2017 Oct; 23(19):5836-5845. PubMed ID: 28679774
[No Abstract] [Full Text] [Related]
14. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
[TBL] [Abstract][Full Text] [Related]
15. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
16. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract][Full Text] [Related]
17. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
19. High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.
Kurnit KC; Steiner M; Lastra RR; Weroha SJ; Cursio J; Lengyel E; Fleming GF; Conzen SD
Gynecol Oncol Rep; 2022 Jun; 41():100987. PubMed ID: 35519002
[TBL] [Abstract][Full Text] [Related]
20. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).
Holmes BJ; Gown AM; Vang R; Ronnett BM; Yemelyanova A
Int J Gynecol Pathol; 2014 Jul; 33(4):425-31. PubMed ID: 24901404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
